The Company hereby submits Outcome of BM held on 14.02.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Simran Farms' board approved its unaudited standalone and consolidated results for Q3 FY26 and the nine months ended 31 December 2025. Standalone Q3 revenue fell about 5% year-on-year to Rs. 23,323.25 lakhs, but net profit jumped sharply to Rs. 109.42 lakhs (from Rs. 12.89 lakhs a year ago), with EPS rising to Rs. 2.89. However, nine-month standalone net profit dropped to Rs. 215.30 lakhs versus Rs. 904.48 lakhs in the same period last year, and EPS for nine months fell to Rs. 5.68 from Rs. 23.85. Consolidated numbers are broadly in line, with subsidiary Puregene Biotech contributing only marginal revenue and profit. The board also accepted the resignation of independent woman director Mrs. Sherry Mac and appointed Adv. Deepika Sharma as a new non-executive woman independent director for five years, alongside a reconstitution of the Audit, Nomination & Remuneration, and Stakeholder Relationship committees.
Mixed signals for shareholders: the strong sequential rebound in Q3 profit is a positive, but the sharp drop in nine-month profit versus last year points to weak earlier quarters. Director and committee changes are routine governance updates and should not materially affect operations.